Alarmins: awaiting a clinical response.

Alarmins are endogenous molecules that are constitutively available and released upon tissue damage and activate the immune system. Current evidence indicates that uncontrolled and excessive release of alarmins contributes to the dysregulated processes seen in many inflammatory and autoimmune conditions, as well as tumorigenesis and cancer spread. Conversely, alarmins have also been found to play a major role in the orchestration of tissue homeostasis, including repair and remodeling in the heart, skin, and nervous system. Here, we provide an update and overview on alarmins, highlighting the areas that may benefit from this clinical translation.

[1]  M. Bustin,et al.  High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses , 2012, The Journal of experimental medicine.

[2]  L. Jørgensen,et al.  S100A8/A9 deficiency in nonhealing venous leg ulcers uncovered by multiplexed antibody microarray profiling , 2011, The British journal of dermatology.

[3]  F. Broere,et al.  Heat shock proteins are no DAMPs, rather 'DAMPERs' , 2011, Nature Reviews Immunology.

[4]  M. Capogrossi,et al.  HMGB1 Attenuates Cardiac Remodelling in the Failing Heart via Enhanced Cardiac Regeneration and miR-206-Mediated Inhibition of TIMP-3 , 2011, PloS one.

[5]  Y. Konttinen,et al.  Expression of Toll-like Receptors and Their Signaling Pathways in Rheumatoid Synovitis , 2011, The Journal of Rheumatology.

[6]  P. Mease The potential roles for novel biomarkers in rheumatoid arthritis assessment. , 2011, Clinical and experimental rheumatology.

[7]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[8]  S. Kaveri,et al.  Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock , 2011, Intensive Care Medicine.

[9]  M. Feldmann,et al.  TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells , 2011, Proceedings of the National Academy of Sciences.

[10]  Huan Yang,et al.  Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. , 2010, Arthritis and rheumatism.

[11]  Jay W Fox,et al.  Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. , 2010, Journal of proteome research.

[12]  R. Maini,et al.  Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? , 2010, The Journal of Immunology.

[13]  W. Nacken,et al.  The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells , 2010, Nature Medicine.

[14]  J. Gerss,et al.  Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. , 2010, JAMA.

[15]  E. Aronica,et al.  Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.

[16]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[17]  M. Bauer,et al.  Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. , 2010, Current molecular medicine.

[18]  Haichao Wang,et al.  High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. , 2010, Inflammation & allergy drug targets.

[19]  M. Boermeester,et al.  Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. , 2009, American journal of respiratory and critical care medicine.

[20]  E. Matteson,et al.  Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. , 2009, Arthritis and rheumatism.

[21]  M. Feldmann,et al.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[22]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[23]  T. Wirth,et al.  TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. , 2009, Bone.

[24]  A. Sauaia,et al.  HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS , 2009, Shock.

[25]  H. Freeze,et al.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. , 2009, Neoplasia.

[26]  F. Brozzi,et al.  S100B's double life: intracellular regulator and extracellular signal. , 2009, Biochimica et biophysica acta.

[27]  D. Stroncek,et al.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer , 2009, Journal of Translational Medicine.

[28]  M. Bianchi,et al.  Dangers In and Out , 2009, Science.

[29]  R. Kang,et al.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation , 2009, Journal of Translational Medicine.

[30]  M. Spielmann,et al.  Human beta‐defensin‐3 promotes wound healing in infected diabetic wounds , 2009, The journal of gene medicine.

[31]  A. Ribas,et al.  HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression , 2009, PLoS medicine.

[32]  M. Bianchi,et al.  Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.

[33]  R. Landewé,et al.  Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[34]  W. Nacken,et al.  Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. , 2008, Arthritis and rheumatism.

[35]  K. Tracey,et al.  The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage , 2008, The Journal of Neuroscience.

[36]  S. Yamada,et al.  Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. , 2008, Cardiovascular research.

[37]  Hiroyuki Aburatani,et al.  The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.

[38]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[39]  P. Rovere-Querini,et al.  HMGB1: a two-headed signal regulating tumor progression and immunity. , 2008, Current opinion in immunology.

[40]  I. Kubota,et al.  High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. , 2008, Cardiovascular research.

[41]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[42]  S. Coffelt,et al.  Tumors sound the alarmin(s). , 2008, Cancer research.

[43]  D. Foell,et al.  RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis , 2008, Carcinogenesis.

[44]  M. Nishibori,et al.  Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[45]  G. Kollias,et al.  Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling , 2008, Arthritis research & therapy.

[46]  B. Funke,et al.  High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart , 2008, Circulation.

[47]  M. Capogrossi,et al.  High-mobility group box 1 protein in human and murine skin: involvement in wound healing. , 2008, The Journal of investigative dermatology.

[48]  Yi Luo,et al.  RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. , 2008, Journal of autoimmunity.

[49]  N. Sevenet,et al.  Gene profiling in human blood leucocytes during recovery from septic shock , 2008, Intensive Care Medicine.

[50]  J. Jones,et al.  A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  U. Andersson,et al.  Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study , 2008, Arthritis research & therapy.

[52]  T. Ganz,et al.  Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. , 2008, Molecular immunology.

[53]  T. Yoshino,et al.  Anti‐high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  M. Bianchi,et al.  High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity , 2007, Immunological reviews.

[55]  W. Nacken,et al.  Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis , 2007, Annals of the rheumatic diseases.

[56]  S. Opal,et al.  Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection , 2007, Critical care.

[57]  J. Roth,et al.  New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment. , 2007, Rheumatology.

[58]  Ruth S. Waterman,et al.  Ovarian cancers overexpress the antimicrobial protein hCAP‐18 and its derivative LL‐37 increases ovarian cancer cell proliferation and invasion , 2007, International journal of cancer.

[59]  P. Delvenne,et al.  Defensins induce the recruitment of dendritic cells in cervical human papillomavirus‐associated (pre)neoplastic lesions formed in vitro and transplanted in vivo , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[61]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[62]  M. Omata,et al.  Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. , 2007, Biochemical and biophysical research communications.

[63]  Herbert J. Zeh,et al.  Masquerader: High Mobility Group Box-1 and Cancer , 2007, Clinical Cancer Research.

[64]  R. Landewé,et al.  Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[65]  K. Tracey,et al.  High mobility group box‐1 protein induces the migration and activation of human dendritic cells and acts as an alarmin , 2007, Journal of leukocyte biology.

[66]  E. Faist,et al.  The impact of endogenous triggers on trauma-associated inflammation , 2006, Current opinion in critical care.

[67]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[68]  F. Marshall,et al.  Human β-Defensin-1, a Potential Chromosome 8p Tumor Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell Carcinoma , 2006 .

[69]  J. Takeda,et al.  Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. , 2006, American journal of respiratory and critical care medicine.

[70]  David C. Lee,et al.  ELEVATED HIGH-MOBILITY GROUP BOX 1 LEVELS IN PATIENTS WITH CEREBRAL AND MYOCARDIAL ISCHEMIA , 2006, Shock.

[71]  M. Manjili,et al.  Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma” , 2006, The Journal of Immunology.

[72]  K. Tracey,et al.  Anti-HMGB1 Neutralizing Antibody Ameliorates Gut Barrier Dysfunction and Improves Survival after Hemorrhagic Shock , 2006, Molecular medicine.

[73]  H. Hammes,et al.  Inhibition of pathologic retinal neovascularization by α-defensins , 2005 .

[74]  D. Foell,et al.  Carboxylated Glycans Mediate Colitis through Activation of NF-κB1 , 2005, The Journal of Immunology.

[75]  S. Müller,et al.  Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation , 2005, Circulation research.

[76]  C. Hawkey,et al.  Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[77]  J. Oppenheim,et al.  Alarmins: chemotactic activators of immune responses. , 2005, Current opinion in immunology.

[78]  A. Sette,et al.  Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis , 2005, The Lancet.

[79]  Peter P. Nawroth,et al.  Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products1 , 2005, The Journal of Immunology.

[80]  M. Keel,et al.  Pathophysiology of polytrauma. , 2005, Injury.

[81]  Hiroshi Yamamoto,et al.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. , 2005, The Journal of clinical investigation.

[82]  I. Douglas,et al.  HMGB1 contributes to the development of acute lung injury after hemorrhage. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[83]  B. Sandstedt,et al.  Antimicrobial protein hCAP18/LL‐37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells , 2005, International journal of cancer.

[84]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[85]  B. Prakken,et al.  Heat-shock proteins induce T-cell regulation of chronic inflammation , 2005, Nature Reviews Immunology.

[86]  P. Rogalla,et al.  Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. , 2005, The American journal of pathology.

[87]  Y. Taira,et al.  The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. , 2005, The Journal of surgical research.

[88]  I. Thorey,et al.  MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. , 2004, Blood.

[89]  K. Clauser,et al.  Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[90]  D. Foell,et al.  Proinflammatory S100 proteins in arthritis and autoimmune disease. , 2004, Arthritis and rheumatism.

[91]  J. Kuja-Panula,et al.  Regulation of monocyte migration by amphoterin (HMGB1). , 2004, Blood.

[92]  J. Davidson,et al.  Migration inhibitory factor‐related protein (MRP)8 and MRP14 are differentially expressed in free‐electron laser and scalpel incisions , 2004, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[93]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[94]  W. Kuis,et al.  CD4+CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis , 2004, The Journal of Immunology.

[95]  C. Berry,et al.  Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  A. Schmidt,et al.  S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.

[97]  M. Bianchi,et al.  Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation , 2004, The Journal of cell biology.

[98]  D. Foell,et al.  Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? , 2004, Annals of the rheumatic diseases.

[99]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  I. H. Engels,et al.  Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. , 2003, The American journal of pathology.

[101]  P. Rouleau,et al.  Blockade of S100A8 and S100A9 Suppresses Neutrophil Migration in Response to Lipopolysaccharide 1 , 2003, The Journal of Immunology.

[102]  Stefan Joos,et al.  HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[103]  H. Harris,et al.  Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. , 2003, Arthritis and rheumatism.

[104]  B. Bresnihan,et al.  Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. , 2003, Arthritis and rheumatism.

[105]  S. Zahler,et al.  An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. , 2003, The Journal of clinical investigation.

[106]  O. Rotstein Modeling the two-hit hypothesis for evaluating strategies to prevent organ injury after shock/resuscitation. , 2003, The Journal of trauma.

[107]  D. Foell,et al.  S100A12 (EN-RAGE) in monitoring Kawasaki disease , 2003, The Lancet.

[108]  A. Bosserhoff,et al.  Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype , 2003, Molecular and Cellular Biology.

[109]  M. Ståhle-Bäckdahl,et al.  The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. , 2003, The Journal of investigative dermatology.

[110]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[111]  L. Kwak,et al.  Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2 , 2002, Science.

[112]  W. van Eden,et al.  Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. , 2002, Arthritis and rheumatism.

[113]  S. Sauerland,et al.  Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase. , 2002, The Journal of trauma.

[114]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[115]  Judith Sylvester,et al.  Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[116]  L. Kwak,et al.  Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens , 2001, The Journal of Immunology.

[117]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[118]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[119]  R. Donato,et al.  S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. , 2001, The international journal of biochemistry & cell biology.

[120]  K. Reinhart,et al.  Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.

[121]  A. Varki,et al.  Two Proteins Modulating Transendothelial Migration of Leukocytes Recognize Novel Carboxylated Glycans on Endothelial Cells1 , 2001, The Journal of Immunology.

[122]  S. Müller,et al.  The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.

[123]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[124]  K. Zatloukal,et al.  Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. , 2001, Cancer research.

[125]  H. Huttunen,et al.  Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.

[126]  Ji Ming Wang,et al.  Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.

[127]  K. Tracey,et al.  HMG-1 as a mediator of acute lung inflammation. , 2000, Journal of immunology.

[128]  N. Wulffraat,et al.  Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[129]  H. Huttunen,et al.  Regulation of cell migration by amphoterin. , 2000, Journal of cell science.

[130]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[131]  T. Martin Cytokines and the acute respiratory distress syndrome (ARDS): A question of balance , 1997, Nature Medicine.

[132]  R. Jonsson,et al.  Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. , 1994, The Journal of rheumatology.

[133]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[134]  R. G. Clerc,et al.  Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis , 1987, Nature.

[135]  C. Krettek,et al.  Immunomodulation in polytrauma and polymicrobial sepsis - where do we stand? , 2011, Recent patents on inflammation & allergy drug discovery.

[136]  Herbert J Zeh,et al.  High-mobility group box 1 and cancer. , 2010, Biochimica et biophysica acta.

[137]  G. de la Rosa,et al.  The alarmin functions of high-mobility group proteins. , 2010, Biochimica et biophysica acta.

[138]  Jong Chun Park,et al.  TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. , 2009, Frontiers in bioscience.

[139]  J. Oppenheim,et al.  Alarmins and antimicrobial immunity. , 2009, Medical mycology.

[140]  M. Bianchi,et al.  Regulation of dendritic- and T-cell fate by injury-associated endogenous signals. , 2009, Critical reviews in immunology.

[141]  Liwu Li,et al.  Macrophages and fibroblasts during inflammation, tissue damage and organ injury. , 2009, Frontiers in bioscience.

[142]  R. Bals,et al.  The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. , 2008, Lung cancer.

[143]  M. Capogrossi,et al.  Pivotal Advance: High-mobility group box 1 protein—a cytokine with a role in cardiac repair , 2006 .

[144]  F. Marshall,et al.  Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. , 2006, Cancer research.

[145]  D. Foell,et al.  Carboxylated glycans mediate colitis through activation of NF-kappa B. , 2005, Journal of immunology.

[146]  H. Hammes,et al.  Inhibition of pathologic retinal neovascularization by alpha-defensins. , 2005, Blood.

[147]  Josefina Garcia Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004 .

[148]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[149]  M. Witz Transected axillary artery: unusual blunt trauma. , 2003, The Journal of trauma.

[150]  K Suzuki,et al.  TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. , 2001, Nature neuroscience.

[151]  M. Polley Renal transplantation. , 1967, Nursing times.

[152]  T. Kislinger,et al.  Blockade of RAGE ± amphoterin signalling suppresses tumour growth and metastases , 2022 .